• 9% increase in recurring revenue in Q1 FY26 versus Q1 FY25
• Delivery of ~$1 million clinical coding audit contract for Singapore's Ministry of Health
• Strong demand for PICQ Audit with 5 new contracts
• 4 new Abbott licences secured for Rippledown

Beamtree Holdings Limited (ASX: BMT), a leading provider of AI decision support and data insights solutions for the healthcare sector, has released a trading and operational update for the first quarter to 30 September 2025 (Q1 FY26) of the current financial year to 30 June 2026 (FY26). The company has continued its strong growth trajectory, delivering a 9% increase in recurring revenue in Q1 FY26 versus Q1 FY25 (+$570k). Key highlights include the delivery of a ~$1 million clinical coding audit contract for Singapore's Ministry of Health, solid expansion in Knowledge Networks through increased subscription volumes, and strong demand for PICQ Audit with 5 new contracts. The company also secured 4 new Abbott licences for Rippledown, contributing 10% of the total recurring revenue uplift for Q1 FY26. Beamtree continues to execute against its strategic roadmap, with key programs of work progressing on schedule across core international markets during Q1 FY26. This includes the deployment of the company's new autonomous clinical coding solution across Australia, Canada, and the UK, and the Evolve collaboration with the NHS Confederation in the UK, which is on track for launch in Q3 FY26. The company has also appointed Stuart MacDonald as a Non-Executive Director, who brings extensive experience in scaling software companies globally.

Beamtree reported a 9% increase in recurring revenue in Q1 FY26 compared to Q1 FY25, driven by growth across all product disciplines including PICQ Audit, coding assistance and data quality audits, new Rippledown sales with Abbott Laboratories, and Knowledge Networks growth in ANZ & The Evolve UK Collaboration.

The continued strong operational momentum following Q4 FY25 was replicated in Q1 FY26, with maturing and extended sales pipeline opportunities, growth in key product lines, and disciplined cost control. The ARR revenue growth, pipeline scale, and procurement discussions continue to provide the Board and Management with confidence in the company's ability to deliver continued financial improvement throughout FY26.